journal article·2023-12Open access

SEMA4D/VEGF surface enhances endothelialization by diminished-glycolysis-mediated M2-like macrophage polarization

Yuanyuan Cui, Xiaomei Jiang, Maozhu Yang, Yinglin Yuan, Zili Zhou, Xiang Gao, Guiqing Jia, Lvzhou Cao, Danni Li, Yanshuang Zhao, Xin Zhang, Gaoping Zhao

Abstract

Cardiovascular disease remains the leading cause of death and morbidity worldwide. Inflammatory responses after percutaneous coronary intervention led to neoathrosclerosis and in-stent restenosis and thus increase the risk of adverse clinical outcomes. In this work, a metabolism reshaped surface is engineered, which combines the decreased glycolysis promoting, M2-like macrophage polarization, and rapid endothelialization property. Anionic heparin plays as a linker and mediates cationic SEMA4D and VEGF to graft electronically onto PLL surfaces. The system composed by anticoagulant heparin, immunoregulatory SEMA4D and angiogenic VEGF endows the scaffold with significant inhibition of platelets, fibrinogen and anti-thrombogenic properties, also noteworthy immunometabolism reprogram, anti-inflammation M2-like polarization and finally leading to rapid endothelializaiton performances. Our research indicates that the immunometabolism method can accurately reflect the immune state of modified surfaces. It is envisioned immunometabolism study will open an avenue to the surface engineering of vascular implants for better clinical outcomes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Angiogenesis and VEGF in Cancer · Extracellular vesicles in disease · Aortic aneurysm repair treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (66)

Show source-provided references
1. Framingham contribution to cardiovascular disease10.4103/1995-705X.185130 ↗
2. Surface engineering of cardiovascular devices for improved hemocompatibility and rapid endothelialization10.1002/adhm.202000920 ↗
3. Endothelialization of cardiovascular devices10.1016/j.actbio.2019.08.042 ↗
4. Cardiovascular stents: a review of past, current, and emerging devices10.3390/ma14102498 ↗
5. Endothelium-Mimicking multifunctional coating modified cardiovascular stents via a stepwise metal-catechol-(amine) surface engineering strategy10.34133/2020/9203906 ↗
6. Titanium-nitride-oxide-coated coronary stents: insights from the available evidence10.1080/07853890.2016.1244353 ↗
7. Inflammation as a determinant of healing response after coronary stent implantation10.1007/s10554-020-02073-3 ↗
8. Comparison of sirolimus-eluting, paclitaxel-eluting, and bare-metal stents in a patient with angina pectoris: histopathological autopsy findings of the third month10.1007/s12928-013-0233-5 ↗
9. J. Macrophages in atherosclerosis regression10.1161/ATVBAHA.119.312802 ↗
10. Exploring the full spectrum of macrophage activation10.1038/nri2448 ↗
11. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages10.1038/ni.2956 ↗
12. Target regulation of both VECs and VSMCs by dual-loading miRNA-126 and miRNA-145 in the bilayered electrospun membrane for small-diameter vascular regeneration10.1002/jbm.a.36548 ↗
13. miR-22 eluting cardiovascular stent based on a self-healable spongy coating inhibits in-stent restenosis
14. Local delivery of dual MicroRNAs in trilayered electrospun grafts for vascular regeneration10.1021/acsami.9b19452 ↗
15. MSC-derived sEVs enhance patency and inhibit calcification of synthetic vascular grafts by immunomodulation in a rat model of hyperlipidemia10.1016/j.biomaterials.2019.01.049 ↗
16. Metabolic adaptations of tissue-resident immune cells10.1038/s41590-019-0407-0 ↗
17. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data10.1016/S0140-6736(18)31114-0 ↗
18. Cardiovascular risk stratification by coronary computed tomography angiography imaging: current state-of-the-art10.1093/eurjpc/zwab067 ↗
19. The predictive value of the perivascular adipose tissue CT fat attenuation index for coronary in-stent restenosis10.3389/fcvm.2022.822308 ↗
20. Soluble SEMA4D/CD100: a novel immunoregulator in infectious and inflammatory diseases10.1016/j.clim.2015.12.012 ↗
21. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice10.1016/S1074-7613(00)00063-7 ↗
22. Endogenous CD100 promotes glomerular injury and macrophage recruitment in experimental crescentic glomerulonephritis10.1111/j.1365-2567.2009.03098.x ↗
23. Intact cd100-CD72 interaction necessary for TCR-induced T cell proliferation10.3389/fimmu.2017.00765 ↗
24. CD8low CD100- T cells identify a novel CD8 T cell subset associated with viral control during human hantaan virus infection10.1128/JVI.01610-15 ↗
25. CD100 on NK cells enhance IFNgamma secretion and killing of target cells expressing CD7210.1371/journal.pone.0000818 ↗
26. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury10.1073/pnas.0606344104 ↗
27. Phage display identification of CD100 in human atherosclerotic plaque macrophages and foam cells10.1371/journal.pone.0075772 ↗
28. Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte activation10.4049/jimmunol.148.2.318 ↗
29. Semaphorins in interactions between T cells and antigen-presenting cells10.1038/nri1003 ↗
30. Sema4D induces angiogenesis through Met recruitment by Plexin B110.1182/blood-2004-07-2885 ↗
31. Situ endothelialization promoted by SEMA4D and CXCL12 for titanium-based biomaterials10.1055/s-0037-1605569 ↗
32. SEMA4D-heparin complexes immobilized on titanium surfaces have anticoagulant, cell-migration-promoting, and immunoregulatory effects
33. Real-time QCM-D monitoring of endothelial cells and macrophages adhering and spreading to SEMA4D/heparin surfaces10.1016/j.colsurfb.2018.07.062 ↗
34. Vascular endothelial growth factor: basic science and clinical progress10.1210/er.2003-0027 ↗
35. VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer10.1186/s11658-017-0058-9 ↗
36. How it all starts: initiation of the clotting cascade10.3109/10409238.2015.1050550 ↗
37. New fundamentals in hemostasis10.1152/physrev.00016.2011 ↗
38. Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease10.1136/jcp.38.10.1166 ↗
39. Karaman · 2018
40. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B10.1158/0008-5472.CAN-04-0126 ↗
41. SEMA4D/PlexinB1 promotes AML progression via activation of PI3K/Akt signaling10.1186/s12967-022-03500-w ↗
42. Vascular smooth muscle cells in intimal hyperplasia, an update
43. Macrophage phenotyping in atherosclerosis by proteomics10.3390/ijms24032613 ↗
44. Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation10.1161/CIRCRESAHA.119.312321 ↗
45. A comparison of drug eluting stent biocompatibility between third generation NOBORI biolimus A9-eluting stent and second generation XIENCE V everolimus-eluting stent in a porcine coronary artery model10.1016/j.carrev.2015.06.009 ↗
46. Immune-inflammatory response after bioresorbable vascular scaffold implantation in patients with acute myocardial infarction with ST elevation in a long-term perspective10.1007/s00380-018-1281-7 ↗
47. Association between inflammatory biomarkers and neointimal response following elective implantation of the ABSORB bioresorbable vascular scaffold10.1097/MCA.0000000000000699 ↗
48. Heparinization and hybridization of electrospun tubular graft for improved endothelialization and anticoagulation10.1016/j.msec.2020.111861 ↗
49. Epigallocatechin gallate mediated sandwich-like coating for mimicking endothelium with sustained therapeutic nitric oxide generation and heparin release10.1016/j.biomaterials.2020.120418 ↗
50. Recent strategies for improving hemocompatibility and endothelialization of cardiovascular devices and inhibition of intimal hyperplasia10.1039/D2TB00478J ↗
51. The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity10.1038/nsmb810 ↗
52. Disruption of SEMA4D ameliorates platelet hypersensitivity in dyslipidemia and confers protection against the development of atherosclerosis10.1161/ATVBAHA.109.185405 ↗
53. Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer10.1038/cr.2011.198 ↗
54. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis10.1038/nrc2404 ↗
55. Plexin-B1 utilizes RhoA and Rho kinase to promote the integrin-dependent activation of Akt and ERK and endothelial cell motility10.1074/jbc.M705467200 ↗
56. Semaphorin 4D/plexin-B1 induces endothelial cell migration through the activation of PYK2, Src, and the phosphatidylinositol 3-kinase-Akt pathway10.1128/MCB.25.16.6889-6898.2005 ↗
57. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis10.1200/JCO.2005.06.081 ↗
58. Overexpression of Semaphorin4D indicates poor prognosis and prompts monocyte differentiation toward M2 macrophages in epithelial ovarian cancer10.7314/APJCP.2013.14.10.5883 ↗
59. Macrophage responses to environmental stimuli during homeostasis and disease10.1210/endrev/bnab004 ↗
60. Glucose metabolism controls disease-specific signatures of macrophage effector functions10.1172/jci.insight.123047 ↗
61. Establishing mammalian GLUT kinetics and lipid composition influences in a reconstituted-liposome system10.1038/s41467-023-39711-y ↗
62. Regulation of macrophage immunometabolism in atherosclerosis10.1038/s41590-018-0113-3 ↗
63. Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the working group on atherosclerosis and vascular biology of the European society of cardiology10.1093/cvr/cvz166 ↗
64. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization10.1016/j.immuni.2015.02.005 ↗
65. M1 means kill; M2 means heal10.4049/jimmunol.1701135 ↗
66. Mitochondrial dysfunction prevents repolarization of inflammatory macrophages10.1016/j.celrep.2016.09.008 ↗